Table 2.
Candidate repurposable drugs for the treatment of COVID-19.
| Drug | DrugBank I.D. | MCF7 Concordance | HA1E Concordance | MOA | ATC Drug Class | Indication |
|---|---|---|---|---|---|---|
| Drugs with reported antiviral activity. | ||||||
| Alvocidib | DB03496 | 0.92 | 0.96 | CDK inhibitor | Unclassified | Antineoplastic |
| Genistein | DB01645 | 0.91 | 0.93 | Tyrosine kinase and topoisomerase-II inhibitor | Unclassified | Antineoplastic; nthelmintic |
| Ivermectin | DB00602 | 0.90 | 0.83 | Chloride channel agonist | Anthelmintic | Anthelmintic |
| Drugs with no reported antiviral activity. | ||||||
| Clinically Relevant Drugs | ||||||
| Idebenone | DB09081 | 0.88 | 0.81 | Electron donor to mitochondrial electron transport chain | Psychoanaleptic | Leber’s Hereditary Optic Neuropathy |
| Penicillin V | DB01053 | 0.97 | 0.80 | Binds penicillin binding proteins, inhibits bacterial cell wall synt hesis | Antibacterials for Systemic Use | Antibiotic |
| Idelalisib | DB09054 | 0.88 | 0.84 | Phosphoinositid e 3-kinase inhibitor | Antineoplastic Agent |
| GSK-1059615 | DB11962 | 0.83 | 0.84 | Phosphoinositid e 3-kinase, mTOR inhibitor 46 | Unclassified |
| AT-9283 | DB05169 | 0.89 | 0.82 | kinase inhibitor | Unclassified |
| Experimental Drugs | |||||
| GSK-3 Inhibitor IX | -- | 0.87 | 0.85 | Inhibitor of glycogen synthase kinase-3a/b 47 | Unclassified |
| AC1MJ3VH | -- | 0.89 | 0.82 | RNA synthesis and topoisomerase inhibitor 48 | Unclassified |
| CCT-10B | -- | 0.95 | 0.90 | #Kinase binding, protein kinase binding | Unclassified |
| CHEMBL2136735 | -- | 0.80 | 0.96 | #Oxidoreductas e activity, cadherin binding | Unclassified |
| Broad-Sai-595 | -- | 0.82 | 0.92 | #NAPH binding, cadherin binding | Unclassified |
| BRD-K54343811 | -- | 0.98 | 0.87 | #Protein tyrosine kinase binding, phosphotyrosin e residue binding | Unclassified |